Katherine K. Matthay
University of California, San Francisco · Children's Hospital Los Angeles
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
6
all conditions, ClinicalTrials.gov
NIH grants tied to them
7
NIH RePORTER
Trial papers
71
PubMed author-name match
Trials
Studies that name Katherine K. Matthay as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00659984 · N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk NeuroblastomaMolecular Insight Pharmaceuticals, Inc. · completed · Neuroblastoma · principal investigator
- Ph2NCT00293319 · 131 I-MIBG in Treating Patients With Refractory or Relapsed NeuroblastomaUniversity of California, San Francisco · completed · Neuroblastoma · study chair
- Ph2NCT00253435 · N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · principal investigator
- Ph1NCT00093353 · N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium · completed · Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma · principal investigator
- Ph1NCT00083135 · N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell TransplantationNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · study chair
- Ph1NCT00005978 · N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Trials and TranslationP01CA217959 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · fiscal years 2017 to 2018 · $561,437 awarded in 2018Same name and institution; not confirmed by an ID
- Pediatric Malignancies ProgramP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2007 to 2018 · $86,469 awarded in 2018Same name and institution; not confirmed by an ID
- CLINICAL THERAPY TRIALSP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · fiscal years 2005 to 2014 · $405,218 awarded in 2014Grant number is on one of their registry trials
- 131 I-LABELED MIBG FOR TREATMENT OF ADVANCED NEUROBLASTOMA: A PHASE II STUDYM01RR001271 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1995 to 2005 · $34,862 awarded in 2005Same name and institution; not confirmed by an ID
- 131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*R21CA097758 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2003 to 2004 · $261,006 awarded in 2004Same name and institution; not confirmed by an ID
- CHILDRENS CANCER GROUPU10CA017829 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1993 to 2002 · $205,002 awarded in 2002Same name and institution; not confirmed by an ID
- TREATMENT OF LEUKEMIA BY ANTIBODY-DIRECTED LIPOSOMESR01CA039448 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1985 to 1991 · $155,457 awarded in 1991Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 71 PubMed records, and a shared surname and initials can bring in a namesake. All 71 on PubMed
- Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.N Engl J Med · 19991,522 citationsRCR 32.7
- Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.N Engl J Med · 20101,421 citationsRCR 32.3
- 702 citationsRCR 15.8
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.Lancet Oncol · 2013243 citationsRCR 7.5
- Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.N Engl J Med · 2010228 citationsRCR 6.1
- Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.J Clin Oncol · 2009191 citationsRCR 5.8
- Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.J Clin Oncol · 2007188 citationsRCR 4.8
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clin Cancer Res · 2021185 citationsRCR 10.4
- Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.J Clin Oncol · 1998174 citationsRCR 4.7
- Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.J Clin Oncol · 2000162 citationsRCR 3.7